$5M
Qualified
maximum offering price, as qualified
—
Reported Sold
no 1-K or 1-Z states a sold amount
4
Filings
across 1 offering
Equity Classes
| Type | Class | Outstanding | CUSIP | Publicly Traded |
|---|---|---|---|---|
| common | COMMON STOCK | 281,635,405 | 29272H300 | OTC.QB |
| debt | N/A | 6,791,359 | — | — |
| preferred | AA | 25,000 | — | — |
| preferred | B | 600 | — | — |
| preferred | C | 738 | — | — |
| preferred | D | 0 | — | — |
Service Providers
| Role | Provider | CRD |
|---|---|---|
| auditor | Rose, Snyder & Jacobs, LLP | — |
| sales commission | Dalmore Group, LLC, | — |
| underwriter | JH Darbie & Co. | 136352 |
Offerings
| File Number | Filings | First Filed | Last Filed | Price/Security | Securities Offered | Outstanding | Aggregate Offering | Estimated Net | CRD |
|---|---|---|---|---|---|---|---|---|---|
| 024-11805 | 4 | 2022-02-11 | 2023-08-25 | $0.01 | 220,000,000 | 281,635,405 | $5M | $4.7M | 136352 |
The statements and reported figures behind ENDONOVO THERAPEUTICS, INC.
Operations, the balance sheet and cash flows as filed, year by year — the filer's own captions, not a mapped chart of accounts — plus the tagged figures from every Form 1-A family filing, plotted on the dates they were actually reported. EDGAR still has each 1-K; the dashboard lays every year they filed next to it.
- Every caption as the filer wrote it, across every annual report — not just the latest 1-K
- Tagged reported figures across every filing — revenue, assets, cash — with a sparkline on the actual filing dates
- A sparkline on each annual-statement line, so the shape is visible before the figures
- A revenue series dated to the filings that reported it
- A filing history that says what each document contributed, not only that it exists
- Follow it, and see it change on your watchlist
External link: SEC Filings